Compare WKSP & NNVC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | WKSP | NNVC |
|---|---|---|
| Founded | 2003 | 2005 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Auto Parts:O.E.M. | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 20.4M | 24.4M |
| IPO Year | N/A | N/A |
| Metric | WKSP | NNVC |
|---|---|---|
| Price | $1.97 | $1.05 |
| Analyst Decision | Strong Buy | |
| Analyst Count | 2 | 0 |
| Target Price | ★ $9.25 | N/A |
| AVG Volume (30 Days) | 158.8K | ★ 294.9K |
| Earning Date | 11-13-2025 | 02-13-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $14,286,679.00 | N/A |
| Revenue This Year | $142.95 | N/A |
| Revenue Next Year | $109.62 | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | ★ 123.37 | N/A |
| 52 Week Low | $1.85 | $0.94 |
| 52 Week High | $11.00 | $2.23 |
| Indicator | WKSP | NNVC |
|---|---|---|
| Relative Strength Index (RSI) | 36.37 | 39.42 |
| Support Level | $1.85 | $1.13 |
| Resistance Level | $2.10 | $1.16 |
| Average True Range (ATR) | 0.15 | 0.06 |
| MACD | -0.02 | -0.00 |
| Stochastic Oscillator | 19.60 | 14.62 |
Worksport Ltd through its subsidiaries, designs, develops, manufactures, and owns the IP on a variety of tonneau covers, solar integrations, and NP (Non-Parasitic), Hydrogen-based true green energy solutions for the sustainable, clean energy, and automotive industries. The company's product includes soft vinyl tonneau covers and hard aluminum tonneau covers. It operates in two reporting segments for financial reporting purposes: Hard Tonneau Covers and Soft Tonneau Covers. Geographically, the company operates in Canada, United States and Other Countries.
Nanoviricides Inc is a nano-biopharmaceutical company that is engaged in discovering, developing, and commercializing therapeutics to advance the care of patients suffering from life-threatening viral infections. The company engaged in the application of nanomedicine technologies to the complex issues of viral diseases. It focuses its research and clinical programs on specific anti-viral therapeutics and is seeking to add to its existing portfolio of products through its internal discovery and clinical development programs and through in-licensing.